COCP · Cocrystal Pharma, Inc.
$1.09
-0.03 (-2.68%)
At close · Aug 17
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“For the six months ended June 30, 2026, the Company recorded a net loss of approximately $5,463 and used approximately $4,856 of cash in operating activities. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$21.38M
Shares
19.26M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.01M
-69.3%
FY2020
Net Income
-$8.83M
+49.5%
FY2025
Gross Margin
21.13%
FY2011
Operating Margin
-475.97%
+261.5pp
FY2020
Diluted EPS
-$0.78
+54.7%
FY2025
Operating Cash Flow
-$8.19M
+50.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | $2.01M | $6.56M | — | — | — | — | — | — | — | $12.71M | — | |
| -$15K | — | — | — | — | — | — | -$19K | -$58K | -$7000 | — | — | — | — | — | — | — | |
| -$3.55M | — | — | — | — | — | — | — | — | — | — | — | — | — | $405.92K | $9.92M | $8.43M | |
| $4.09M | — | — | — | — | — | — | — | — | — | — | — | — | — | $7.22M | $2.69M | $6.83M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 21.13% | — | |
| $6.09M | $5.06M | $12.54M | $15.17M | $12.39M | $8.79M | $6.03M | $4M | $4.67M | $5.82M | $101.68M | $47.26M | $4.07M | $3.86M | $489.35K | $423.18K | $240.87K | |
| $679.58K | — | — | — | — | — | — | — | — | — | — | — | — | — | $774.78K | $678.34K | — | |
| $4.35M | $3.96M | $5.34M | $5.99M | $5.75M | $5.43M | $5.57M | $4.86M | $4.35M | $2.44M | $4.14M | $6.77M | $1.74M | $219K | $2.06M | $5.47M | $6.62M | |
| — | $72K | $126K | $189K | $185K | $190K | $157K | $76K | $6000 | $101K | $201K | $192K | $199K | $236K | $138.59K | $531.84K | $432.57K | |
| $10.44M | $9.02M | $17.88M | $18.56M | $38.83M | $14.22M | $11.6M | $54.97M | $62.92M | $8.26M | $105.82M | $54.03M | $5.81M | $4.08M | $2.55M | $6.57M | $6.86M | |
| -$10.11M | -$9.02M | -$17.88M | -$18.56M | -$38.83M | -$14.22M | -$9.59M | -$48.41M | -$62.92M | -$8.26M | -$105.82M | -$53.95M | -$5.8M | -$4.08M | -$2.55M | -$3.89M | -$32.05K | |
| — | — | — | — | — | — | -475.97% | -737.45% | — | — | — | — | — | — | — | -30.58% | — | |
| — | -$8.95M | -$17.75M | -$18.37M | -$38.64M | -$14.03M | -$9.43M | -$48.33M | -$62.92M | -$8.16M | -$105.62M | -$53.76M | -$5.6M | -$3.85M | -$2.41M | -$3.36M | $400.52K | |
| -$101K | -$134K | -$537K | -$640K | $2000 | $4000 | $8000 | $19K | $58K | — | — | — | — | -$3.34M | -$5.23M | -$1.24M | -$439.02K | |
| $172K | $188K | $374K | $575K | -$8000 | $36K | -$62K | $237K | $294K | $769K | $1.55M | -$11.42M | $5.65M | $194K | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$42.68K | $55.31K | |
| — | -$8.83M | -$18.63M | — | — | — | -$9.65M | -$48.17M | -$62.63M | -$7.49M | -$104.27M | -$65.37M | -$151K | -$3.89M | -$7.63M | -$5.45M | -$415.76K | |
| — | — | — | — | — | — | — | — | -$13.58M | -$6.88M | -$29.39M | -$15.25M | -$52K | — | — | $3272 | -$95.95K | |
| -$9.94M | -$8.83M | -$17.5M | -$17.98M | -$38.84M | -$14.19M | -$9.65M | -$48.17M | -$49.05M | -$613K | -$74.87M | -$50.12M | -$99K | -$3.89M | -$7.96M | -$5.46M | -$319.81K | |
| — | — | — | — | — | — | -479.05% | -733.84% | — | — | — | — | — | — | — | -42.93% | — | |
| — | — | — | — | — | — | — | -$48.17M | -$49.05M | -$613K | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | -$74.87M | -$50.12M | $137K | -$3.89M | — | — | — | |
| USD/shares | — | -$0.78 | -$1.72 | -$1.87 | -$4.77 | -$0.16 | — | — | — | -$0.36 | -$38.16 | -$28.80 | $0.00 | -$0.84 | -$1.56 | -$1.32 | -$0.12 |
| USD/shares | — | -$0.78 | -$1.72 | -$1.87 | -$4.77 | — | — | — | — | -$0.36 | -$39.60 | -$28.80 | -$0.12 | -$0.84 | — | — | — |
| shares | — | 11.29M | 10.17M | 9.65M | 8.14M | 7.36M | 4.6M | 2654.9167 | 2334.0833 | 2.01M | 1.96M | 1.75M | 27.23M | 4771.25 | — | 4.2M | — |
| shares | — | 11.29M | 10.17M | 9.65M | 8.14M | 7.36M | 4.6M | 2654.9167 | 2334.0833 | 2.01M | 1.96M | 1.75M | 27.31M | 4771.25 | 5.14M | 4.2M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.64×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.97×
Peer medians compare against the 249 similar-size Biotechnology companies (of 545 listed).
Key facts
CIK
1412486
CUSIP
19188J409
13F (30d)
29 filings
29 filers
Visit website
Investor relations